On November 29, 2022, Susan Kalled, PhD departed her position as Chief Scientific Officer of Compass Therapeutics, Inc. Dr. Kalled’s Employment Agreement with the Company, dated April 26, 2021 provides, among other things, that, subject to signing a separation agreement and release in a form and manner satisfactory to the Company, Dr. Kalled will (1) receive severance equal to twelve months of her base salary, payable in substantially equal installments in accordance with the Company’s payroll practice over twelve months and (2) receive reimbursement of COBRA premiums for health benefit coverage or remain eligible to participate in the Company’s group employee benefits plan for up to twelve months, all subject to certain conditions, including that Dr. Kalled has not breached any of her continuing obligations, including those under the separation agreement and release.